Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma

doyoung kim, SangHoon Ahn, Seungup Kim, Sae Byeol Choi, Kwang Hun Lee, Mi Sook Park, Junyong Park, Do Yun Lee, KwangHyub Han, Kyung Sik Kim

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objectives: We investigated whether adjuvant hepatic arterial infusional chemotherapy (HAIC) with 5-fluorouracil (5-FU) and cisplatin reduces the recurrence of hepatocellular carcinoma (HCC) after curative resection. Methods: Between January 2006 and December 2008, 31 HCC patients received four cycles of adjuvant HAIC with 5-FU and cisplatin via port system after curative resection. During the same period, 62 patients, who did not take any adjuvant therapy, were selected as controls. Results: Tumor characteristics, such as distribution of TNM stage, pathologic differentiation, portal vein invasion, or microscopic invasion did not differ between control and adjuvant groups. During follow-up, recurrence developed in 11 adjuvant (35.5%) and 24 control patients (38.7%; p = 0.823). Tumor progression after recurrence was the cause of death in 2 adjuvant (28.6%) and 7 control patients (38.8%; p = 0.912). The 2-year recurrence rate was 9.1% in the adjuvant group and 4.2% in the control group, with the median recurrence-free survival time being 10.5 and 7.5 months, respectively (p = 0.324). The 3-year cumulative survival rate was 73.3% in the adjuvant group and 68.3% in the control group (p = 0.355). Conclusion: Adjuvant HAIC with 5-FU and cisplatin did not offer any beneficial effect on the recurrence after curative resection of HCC.

Original languageEnglish
Pages (from-to)184-191
Number of pages8
JournalOncology
Volume81
Issue number3-4
DOIs
Publication statusPublished - 2011 Dec 1

Fingerprint

Fluorouracil
Cisplatin
Hepatocellular Carcinoma
Recurrence
Drug Therapy
Liver
Control Groups
Portal Vein
Cause of Death
Neoplasms
Survival Rate
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{01196b166a0c45dd8f918d67f11efc62,
title = "Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma",
abstract = "Objectives: We investigated whether adjuvant hepatic arterial infusional chemotherapy (HAIC) with 5-fluorouracil (5-FU) and cisplatin reduces the recurrence of hepatocellular carcinoma (HCC) after curative resection. Methods: Between January 2006 and December 2008, 31 HCC patients received four cycles of adjuvant HAIC with 5-FU and cisplatin via port system after curative resection. During the same period, 62 patients, who did not take any adjuvant therapy, were selected as controls. Results: Tumor characteristics, such as distribution of TNM stage, pathologic differentiation, portal vein invasion, or microscopic invasion did not differ between control and adjuvant groups. During follow-up, recurrence developed in 11 adjuvant (35.5{\%}) and 24 control patients (38.7{\%}; p = 0.823). Tumor progression after recurrence was the cause of death in 2 adjuvant (28.6{\%}) and 7 control patients (38.8{\%}; p = 0.912). The 2-year recurrence rate was 9.1{\%} in the adjuvant group and 4.2{\%} in the control group, with the median recurrence-free survival time being 10.5 and 7.5 months, respectively (p = 0.324). The 3-year cumulative survival rate was 73.3{\%} in the adjuvant group and 68.3{\%} in the control group (p = 0.355). Conclusion: Adjuvant HAIC with 5-FU and cisplatin did not offer any beneficial effect on the recurrence after curative resection of HCC.",
author = "doyoung kim and SangHoon Ahn and Seungup Kim and Choi, {Sae Byeol} and Lee, {Kwang Hun} and Park, {Mi Sook} and Junyong Park and Lee, {Do Yun} and KwangHyub Han and Kim, {Kyung Sik}",
year = "2011",
month = "12",
day = "1",
doi = "10.1159/000333827",
language = "English",
volume = "81",
pages = "184--191",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "3-4",

}

Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma. / kim, doyoung; Ahn, SangHoon; Kim, Seungup; Choi, Sae Byeol; Lee, Kwang Hun; Park, Mi Sook; Park, Junyong; Lee, Do Yun; Han, KwangHyub; Kim, Kyung Sik.

In: Oncology, Vol. 81, No. 3-4, 01.12.2011, p. 184-191.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma

AU - kim, doyoung

AU - Ahn, SangHoon

AU - Kim, Seungup

AU - Choi, Sae Byeol

AU - Lee, Kwang Hun

AU - Park, Mi Sook

AU - Park, Junyong

AU - Lee, Do Yun

AU - Han, KwangHyub

AU - Kim, Kyung Sik

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Objectives: We investigated whether adjuvant hepatic arterial infusional chemotherapy (HAIC) with 5-fluorouracil (5-FU) and cisplatin reduces the recurrence of hepatocellular carcinoma (HCC) after curative resection. Methods: Between January 2006 and December 2008, 31 HCC patients received four cycles of adjuvant HAIC with 5-FU and cisplatin via port system after curative resection. During the same period, 62 patients, who did not take any adjuvant therapy, were selected as controls. Results: Tumor characteristics, such as distribution of TNM stage, pathologic differentiation, portal vein invasion, or microscopic invasion did not differ between control and adjuvant groups. During follow-up, recurrence developed in 11 adjuvant (35.5%) and 24 control patients (38.7%; p = 0.823). Tumor progression after recurrence was the cause of death in 2 adjuvant (28.6%) and 7 control patients (38.8%; p = 0.912). The 2-year recurrence rate was 9.1% in the adjuvant group and 4.2% in the control group, with the median recurrence-free survival time being 10.5 and 7.5 months, respectively (p = 0.324). The 3-year cumulative survival rate was 73.3% in the adjuvant group and 68.3% in the control group (p = 0.355). Conclusion: Adjuvant HAIC with 5-FU and cisplatin did not offer any beneficial effect on the recurrence after curative resection of HCC.

AB - Objectives: We investigated whether adjuvant hepatic arterial infusional chemotherapy (HAIC) with 5-fluorouracil (5-FU) and cisplatin reduces the recurrence of hepatocellular carcinoma (HCC) after curative resection. Methods: Between January 2006 and December 2008, 31 HCC patients received four cycles of adjuvant HAIC with 5-FU and cisplatin via port system after curative resection. During the same period, 62 patients, who did not take any adjuvant therapy, were selected as controls. Results: Tumor characteristics, such as distribution of TNM stage, pathologic differentiation, portal vein invasion, or microscopic invasion did not differ between control and adjuvant groups. During follow-up, recurrence developed in 11 adjuvant (35.5%) and 24 control patients (38.7%; p = 0.823). Tumor progression after recurrence was the cause of death in 2 adjuvant (28.6%) and 7 control patients (38.8%; p = 0.912). The 2-year recurrence rate was 9.1% in the adjuvant group and 4.2% in the control group, with the median recurrence-free survival time being 10.5 and 7.5 months, respectively (p = 0.324). The 3-year cumulative survival rate was 73.3% in the adjuvant group and 68.3% in the control group (p = 0.355). Conclusion: Adjuvant HAIC with 5-FU and cisplatin did not offer any beneficial effect on the recurrence after curative resection of HCC.

UR - http://www.scopus.com/inward/record.url?scp=84255170904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84255170904&partnerID=8YFLogxK

U2 - 10.1159/000333827

DO - 10.1159/000333827

M3 - Article

C2 - 22067673

AN - SCOPUS:84255170904

VL - 81

SP - 184

EP - 191

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 3-4

ER -